Lotus Pharmaceutical Co Ltd Asset Resilience Ratio
Lotus Pharmaceutical Co Ltd asset resilience ratio. Lotus Pharmaceutical Co Ltd (1795) has an Asset Resilience Ratio of 0.49% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 1795 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lotus Pharmaceutical Co Ltd (2009–2022)
Asset resilience ratio of Lotus Pharmaceutical Co Ltd from 2009 to 2022. This chart shows how Lotus Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Lotus Pharmaceutical Co Ltd (1795) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lotus Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Lotus Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$169.90 Million | 0.49% |
| Total Liquid Assets | NT$169.90 Million | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Lotus Pharmaceutical Co Ltd maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lotus Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Lotus Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Lotus Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2009–2022)
Lotus Pharmaceutical Co Ltd asset resilience ratio by year from 2009 to 2022. The table below shows the annual Asset Resilience Ratio data for Lotus Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.04% | NT$-10.91 Million ≈ $-343.82K |
NT$29.53 Billion ≈ $930.23 Million |
-0.20pp |
| 2016-12-31 | 0.17% | NT$25.35 Million ≈ $798.76K |
NT$15.24 Billion ≈ $480.27 Million |
-0.16pp |
| 2015-12-31 | 0.32% | NT$49.99 Million ≈ $1.58 Million |
NT$15.50 Billion ≈ $488.40 Million |
-0.13pp |
| 2014-12-31 | 0.46% | NT$74.16 Million ≈ $2.34 Million |
NT$16.27 Billion ≈ $512.60 Million |
-3.88pp |
| 2013-12-31 | 4.33% | NT$86.70 Million ≈ $2.73 Million |
NT$2.00 Billion ≈ $63.03 Million |
-0.33pp |
| 2012-12-31 | 4.66% | NT$50.61 Million ≈ $1.59 Million |
NT$1.09 Billion ≈ $34.19 Million |
-1.29pp |
| 2011-12-31 | 5.95% | NT$66.70 Million ≈ $2.10 Million |
NT$1.12 Billion ≈ $35.31 Million |
+5.67pp |
| 2009-12-31 | 0.28% | NT$2.00 Million ≈ $63.01K |
NT$706.92 Million ≈ $22.27 Million |
-- |
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more